Clinical trials: Single Women
Carcinosarcoma of Ovary, Carcinosarcoma of Uterus
Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
The purpose of this study is to test the safety of Cabozantinib in combination with Nivolumab and Ipilimumab and see what affects that this combination treatment has on those with recurrent carcinosarcomas.
- Conditions
- Carcinosarcoma of Ovary, Carcinosarcoma of Uterus, Carcinosarcoma of Vagina
- Trial name
- NCT04149275
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Breast Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with hormone therapy in Indian women with advanced breast cancer.
- Trial name
- NCT04707196
- Testing
- Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI), Fulvestrant
- Where
- 15 sites in India
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Urolithiasis
Comparing Previously Placed Nephrostomy Tract (NT) Versus Single Stage Percutaneous Nephrolithotomy (PCNL)
The investigators are trying to determine whether placement of a nephrostomy tube prior to definitive stone surgery and under ultrasonic or fluoroscopic guidance will reduce complications related to bleeding and infection compare…
- Trial name
- NCT00907946
- Testing
- NT 1 day before PCNL
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Washington University School of Medicine
Pharmacokinetics
Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women
The purpose of this study is to determine the pharmacokinetic (PK) parameters of vortioxetine after single and multiple oral dosing to healthy Chinese men and women.
- Trial name
- NCT02386488
- Testing
- Vortioxetine 10 mg single dose, Vortioxetine 20 mg single dose, Vortioxetine 10 mg multiple dose
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy Participants
A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential
The main purpose of the study is to assess the effect of multiple doses of baxdrostat on the pharmacokinetics (PK) of a single dose of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG).
- Trial name
- NCT06657105
- Testing
- EE/LNG, Baxdrostat
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Menopause
Single-Dose Study of Black Cohosh and Red Clover
This Phase I study will assess the pharmacokinetics of two botanicals, Trifolium pratense (red clover) and Cimicifuga racemosa (black cohosh). Participants will receive a single dose of one botanical preparation.
- Trial name
- NCT00010959
- Testing
- Cimicifuga racemosa, Trifolium pratense
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
End-Stage Renal Disease
A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and pharmacodynamics (the way a drug may change body function) of a single 15-milligram…
- Trial name
- NCT02289703
- Testing
- Rivaroxaban 15 mg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions
To demonstrate the relative bioequivalence of Cefdinir and Omnicel 250mg/5 ml fasting conditions.
- Trial name
- NCT00882570
- Testing
- Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria), Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sandoz
Urologic Neoplasms
Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy
Ureteral double- J stent is usually inserted by retrograde approach for the treatment of obstructed upper urinary tract. The antegrade approach, can a suitable alternative in certain situations without the need for general or…
- Trial name
- NCT04649970
- Testing
- Antegrade double-J stent
- Volunteers
- 174 people
- Sponsor
- Université de Sousse
Bladder Cancer
Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
This is a multicenter, single-arm study to evaluate the efficacy and safety of Pseudomonas aeruginosa the treatment of patients with intermediate and high risk non-muscle invasive bladder cancer.
- Trial name
- NCT05975151
- Testing
- Pseudomonas aeruginosa
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Qilu Hospital of Shandong University
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Renal Impairment, End-stage Renal Disease
An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
The purpose of this study is to evaluate the percentage of participants with sustained virologic response 12 weeks after the actual end of study treatment (SVR12)
- Trial name
- NCT02397395
- Testing
- Simeprevir (SMV) 150 mg, Daclatasvir (DCV) 60 mg
- Where
- 6 sites in France, Spain
- Sponsor
- Janssen R&D Ireland
MCNS, Minimal Change Nephrotic Syndrome (MCNS)
A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome
To compare the therapeutic effect of tacrolimus in combination with low-dose corticosteroid with high-dose corticosteroid alone in patients with minimal-change nephrotic syndrome.
- Trial name
- T-OPTIMUM (NCT01763580)
- Testing
- Tacrolimus, Prednisolone
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Astellas Pharma Korea, Inc.
Vaginosis, Bacterial
Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14
The purpose of this study was to determine whether L. rhamnosus GR-1 and L. reuteri RC-14 delivered via capsules to the vagina of post-menopausal women over a three day course of treatment can restore and maintain a…
- Trial name
- NCT02139839
- Testing
- Lactobacillus capsules
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Kimberly-Clark Corporation
Breast Cancer
An Enhanced Artificial Intelligence Breast MRI Interpretation System
Interpretation of breast MR images is a very time-consuming process and places a great burden on breast radiologists. This project aims to develop a technical solution that addresses this healthcare challenge by developing a…
- Trial name
- IntelliScan (NCT03829423)
- Testing
- Breast MRI interpretation
- Volunteers
- 1,526 people
- Sponsor
- Jamil Kanfoud
Ovarian Cancer, Ovarian Carcinoma
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
A number of studies suggest that the combination of PARP inhibitors and antiangiogenic agents produce synergistic activities. Pamiparib is a small molecule inhibitor selectivity for both PARP1 and PARP2.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Fallopian Tube Carcinosarcoma
- Trial name
- NCT05494580
- Testing
- Pamiparib, Surufatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-sen University
Ovarian Cancer, Epithelial
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian…
- Trial name
- NCT05422183
- Testing
- Envafolimab, Lenvatinib, VP-16
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zhongda Hospital
Healthy
PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers
This Phase 1, single-dose study will be conducted in adult female subjects (N = 16) who are in general good health and selected for participation in the study according to the selection criteria.
- Trial name
- NCT02553356
- Testing
- PT2385
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Female Infertility
Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in IVF Cycles
The purpose of this study is to evaluate the effect on LH levels of the 5-day CC administration during luteal phase in oocyte donors, to investigate whether the CC corrects the suppressed LH levels in the luteal phase and whether…
- Trial name
- CLOFA (NCT01791751)
- Testing
- Clomifene Citrate
- Where
- Spain
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Fundació Privada Eugin
Healthy
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity
This study is open to healthy people and people with overweight or obesity. It has 2 parts. Part A is open to healthy men between 18 and 55 years of age.
- Trial name
- NCT06352437
- Testing
- BI 3034701
- Where
- Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.